Many of the most common #longCOVID symptoms are neurological - #fatigue, #brainfog, cognitive slowing, and memory decline. Research indicates that lingering #inflammation & #biological changes associated with accelerated #aging may be driving these effects in some patients.
REMINDER BioVie to Host Live Investor Webinar and Q&A on Wednesday, March 4 at 4:15 p.m. ET
A reminder to join us tomorrow for a live webinar with our CEO, Cuong Do, discussing bezisterim’s effects on #inflammation and insulin resistance, two key drivers of #Alzheimer’s, #Parkinson’s, and #LongCOVID.
Register here: www.redchip.com/webinar/BIVI...
#Neuroscience $BIVI
Our CMO, Dr. Joseph Palumbo joined The Innovators Podcast to discuss BioVie’s mission to develop new treatments for #neurological & #neurodegenerative disorders & what it takes to bring a drug from idea to clinic.
Listen here: open.spotify.com/episode/1UZX...
#Parkinsons #LongCOVID #Alz
CORPORATE UPDATE BioVie to Host Live Investor Webinar and Q&A on Wednesday, March 4
Our CEO, Cuong Do, will share updates on bezisterim for the treatment of neurological & neurodegenerative diseases during a live webinar on Wednesday, March 4.
Register here: investors.bioviepharma.com/news/news-de...
#Alzheimers #Parkinsons #LongCOVID #Neuroinflammation #InsulinResistance $BIVI
Image of two people holding hands with the words Thank you Caregivers
Behind every person living with a neurological disease or disorder is a network of caregivers: family, friends, professionals, & advocates who provide essential support. On #NationalCaregiversDay, and every day, we recognize the critical role they play and say THANK YOU! #Alz #Parkinsons #LongCOVID
While the higher reported symptom burden in the U.S. may reflect lower stigma and greater access to neurological and mental healthcare rather than more severe disease, #brainfog and #fatigue were among the most common neurological symptoms across all countries. #LongCOVID
#Parkinson’s care has focused on dopamine for decades.
BioVie ($BIVI) is testing a different angle: targeting brain inflammation + insulin resistance.
Phase 2 SUNRISE-PD enrollment complete with topline data expected Apr/May 2026.
Multiple 2026 catalysts ahead.
#Biotech #BIVI
American College of Psychiatrists Annual Meeting Poster Presentations February 18, 2026 Abstract Title: Bezisterim-Associated Anti-inflammatory Epigenetic Modulation of Age Acceleration and Cognition in Alzheimer's Disease Authors: Joseph M. Palumbo; Christopher L. Reading; Jiayan Yan, Clarence Ahlem; Penelope Markham; Stephen O'Quinn; Varun B. Dwaraka Abstract Title: Baseline Characteristics of Currently Enrolled Participants in Phase 2 Study of Bezisterim (NE3107) in Long COVID (ADDRESS-LC) Authors: Joseph M. Palumbo; Penelope Markham; Michael Peluso; Igor J. Koralnik; Sherry Hsiang-Yi Chou; Lisa McCorkell; Chantal Petit; Stephen O'Quinn; Chris Reading; Clarence Ahlem; Jiayan Yan
BioVie announced the acceptance of two abstracts from studies on our lead candidate bezisterim, in the treatment of #Alzheimer’s & #LongCOVID at the upcoming 2026 American College of Psychiatrists (ACP) annual meeting.
Read: investors.bioviepharma.com/news/news-de...
#ScientificExchange #BIVI
📍There are 18 sites actively recruiting across the U.S.
To learn more about participating in the ADDRESS-LC trial visit addresslongcovid.com
Together, these organizations have given voice to millions suffering in silence. Our team, and #LongCOVID patients, researchers, & doctors are grateful for your active participation + determination to advance research toward a treatment. THANK YOU! 🧡
#Advocacy #PatientCentricResearch
Advancing Science with Support from Advocacy Partners THANK YOU Logo Solve M.E. Logo Patient-Led Research Collaborative
BioVie’s current P2 ADDRESS-LC clinical trial evaluating bezisterim for the treatment of neurological symptoms associated with #LongCOVID was designed to address the unmet needs of the community and made possible with support from @solveme.bsky.social & @patientled.bsky.social.
THANK YOU #MichaelJFoxFoundation, #DavisPhinneyFoundation, & @parkinsondotorg.bsky.social!
Our team, and the Parkinson’s community at large, is grateful for your fierce dedication to advancing research toward treatments for patients.
#ParkinsonsDisease #Advocacy #PatientCentricResearch #BIVI
Advancing Science with Support from Advocacy Partners THANK YOU Logos for: The Michael J. Fox Foundation for Parkinson's Research Davis Phinney Foundation for Parkinson's Parkinson's Foundation
Enrollment in BioVie’s Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for the treatment of motor & non-motor symptoms in patients with early-stage #Parkinson’s disease was made possible with the support of leading advocacy organizations.
Clinical Trials & Pharma Engagement:
• Worked with @biovie.bsky.social on study design & recruitment for their Bezisterim trial for #LongCovid, an investigational drug that has shown promise in neurodegenerative conditions. /5
Our CEO, Cuong Do, spoke with @charlespiller.bsky.social about patterns of alleged misconduct at certain South Florida clinical trial sites, and the devastating implications for the Alzheimer’s community- from patients & families to researchers & drug developers seeking to make a difference.
Parkinson's Update BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease
Enrollment is complete in our Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for the treatment of motor & non-motor symptoms in patients with early-stage #Parkinson’s disease. Topline results expected in 1H 2026.
Learn more: investors.bioviepharma.com/news/news-de...
#Neurology #BIVI
At BioVie, we are actively studying bezisterim in Long COVID - for information about the currently enrolling ADDRESS-LC trial visit addresslongcovid.com
Read the study here www.nature.com/articles/s41...
#Neuroinflammation #InsulinResistance #LongCOVID
“Bezisterim has demonstrated the ability to modulate key inflammatory pathways implicated in the chronic inflammation seen in long COVID, that also play a key role in neurodegenerative diseases of aging, like Parkinson’s and Alzheimer’s.” -Cuong Do President & CEO, BioVie
A study published in @natimmunol.nature.com provides additional evidence that #LongCOVID is associated with chronic #inflammation & metabolic dysregulation. The findings align w/ the MoA of bezisterim, which targets upstream immune signaling involved in chronic inflammation.
#BrainFog #Fatigue
Our CEO, Cuong Do, provided an update on the company’s lead candidate bezisterim currently in clinical trials for patients with #Parkinsons’s & #longCOVID.
Learn about clinical & regulatory catalysts in 2026
www.youtube.com/watch?v=_RI6...
#Neuroinflammation #InsulinResistance #Neuroscience
On a recent episode of Power to the Patients, our CMO Dr. Joseph Palumbo discussed why #inflammation is emerging as a critical factor in treating #neurodegenerative diseases like #Alzheimer's & #Parkinson's.
Listen here: www.youtube.com/watch?v=LNXV...
#Neuroscience #InsulinResistance #LongCOVID
“GREAT TRIALS are testing a hypothesis or have endpoints that can be observed very objectively with quantifiable metrics. That’s the number one criteria. Second, you try to minimize variability. This is where your inclusion and exclusion criteria are critical. And then of course, you’ve got to have the right people out there executing your trial.” -Cuong Do President & CEO, BioVie
On a recent episode of Power to the Patients podcast, our CEO Cuong Do shares how BioVie is focused on the role of #inflammation & #insulinresistance, key drivers of #Alzheimer’s, #Parkinson’s, & #LongCOVID.
Listen here: bit.ly/3Kdr6nE
Watch: lnkd.in/gCxPufWc
#ClinicalTrials
CONGRATULATIONS! Wendy Kim Honored in FEI Silicon Valley Chapter Women CEO of the Year Awards Photo of Wendy Kim Chief Financial Officer, BioVie
BioVie is proud to announce that our CFO Wendy Kim was selected as a winner of the Third Annual Women CFOs of the Year Awards by the @feisv.bsky.social chapter honoring outstanding finance leaders for their achievements.
bit.ly/4rBiQP3
#LifeSciences #BiotechLeadership
November National FAMILY CAREGIVERS Month and National ALZHEIMER'S DISEASE AWARENESS Month Image of a heart with two hands inside attached to a ribbon
This month we honor those living with #Alzheimer’s and the families, clinicians, & researchers supporting them. And THANK YOU to the millions of #caregivers providing essential, heartfelt assistance to loved ones with #neurodegenerative disorders.
#AlzheimersDiseaseAwareness #FamilyCaregiversMonth
LONG COVID UPDATE BioVie Presents at 3rd Long COVID International Conference 2025 November 19-20, 2025 A Phase 2 Trial Designed to Enhance Signal Detection in an Evaluation of Bezisterim (NE3107) for the Treatment of Neurological Symptoms of Long COVID
We’re at #LongCOVIDIntl 2025 presenting our ongoing P2 ADDRESS-LC trial evaluating the efficacy, safety, & tolerability of bezisterim in participants with #LongCOVID enriched for #BrainFog & #fatigue.
Learn about the currently enrolling trial: www.addresslongcovid.com
@academicmededu.bsky.social
REPLAY AVAILABLE Investor Webinar and Q&A Cuong Do President & CEO, BioVie
Earlier this month our CEO held a virtual investor webinar to discuss bezisterim for the treatment of neurological & neurodegenerative diseases.
Catch the replay here: www.youtube.com/watch?v=ts_1...
#Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID $BIVI
PRESENTATION Bezisterim Effects on Aging in Alzheimer's Subjects Chris Reading, PhD Senior Vice President Alzheimer's Disease Program
Dr. Chris Reading, SVP of our Alzheimer’s program, presented at Longevity Biotech 2025 in Boston. He discussed bezisterim’s multifaceted MoA, targeting #inflammation & #insulinresistance in the brain, 2 key drivers of #neurodegenerative disease.
#Longevity #Biotech #Aging #AlzheimersDisease
INVESTOR WEBINAR and Q&A Date: Wednesday, October 8, 2025 Time: 4:15 p.m. EST
A reminder to join us tomorrow for a live webinar with our CEO, Cuong Do, discussing bezisterim for the treatment of neurological & neurodegenerative diseases.
Register here: investors.bioviepharma.com/news/news-de...
#Inflammation #InsulinResistance #Alzheimers #Parkinsons #LongCOVID
Corporate Update BioVie to Host Live Investor Webinar and Q7A on Wednesday, October 8
Our CEO, Cuong Do, will share updates on bezisterim for the treatment of neurological & neurodegenerative diseases during a live webinar on October 8.
Register here: investors.bioviepharma.com/news/news-de...
#Neuroinflammation #InsulinResistance
#Alzheimers #Parkinsons #LongCOVID #NeuroSky
On #WorldAlzheimersDay, we recognize the nearly 60M people worldwide living w/ Alzheimer’s & other forms of dementia.
We're committed to advancing the science of #neuroinflammation -a root cause of #Alzheimer’s, #Parkinson’s & other diseases of #aging.
#InsulinResistance #BIVI
For information about the currently enrolling ADDRESS-LC trial in the U.S., visit addresslongcovid.com
